Table 1. Summary of clinical data corresponding to HIV+ subjects enrolled per study group.
| Viral loada , c | ||||||
| Group (No. of subjects) | Median Days post-infection (IQ) | Median RNA copies/ml (IQ) | Mean log10 ± SD | Viral set pointd (mean log10 ± SD) | CD4+ T-cell countb , c, median No. of cells/µl (IQ) | CD4 set pointd, median No. of cells/µl (IQ) |
| PHI | ||||||
| All (n = 32) | 60 (30–90) | 34,800 (8,843–252,588) | 4.6±0.9 | 4.5±0.7 | 503 (320–682) | 517 (404–629) |
| PHI >350 (n = 20) | 60 (49–113) | 18,471 (6,010–98,650) | 4.3±0.9 | 4.3±0.6 | 618 (510–771) | 573 (454–652) |
| PHI <350 (n = 12) | 55 (30–90) | 151,026 (34,510–500,000) | 5.1±0.8 | 5.1±0.7 | 281 (230–338) | 256 (158–319) |
| Chronic (n = 10) | - | 28,435 (9,449–197,984) | 4.5±0.7 | 141 (11–563) | ||
| EC (n = 11) | - | <50 | <1.7 | 602 (562–888) | ||
a
Versant HIV-1 RNA 3.0 assay, Siemens. Lower and upper detection limits are 50 and 500,000 RNA copies/ml, respectively (1.7 and 5.7log10).
b
Flow cytometry double platform, FACSCanto, BD Biosciences.
c
For PHI subjects, data correspond to baseline samples. For chronic and elite controller subjects, data correspond to samples obtained at enrollment.
d
Set points were not calculated for subjects that initiated HAART during the first year post-infection.
IQ: Interquartile range.